Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Antibiotics, the most common co-covered peer. Each story carries 7 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Antibiotics, the most common co-covered peer. Each story carries 7 original sources on average, compared with 3.6 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 147-day span. Their average consequence score of 7 runs above the beat's 6.2 for that window. This profile follows 2 Biotech stories mentioning Australian Government across the period from February 19, 2026 to July 15, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 554 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Australian Government. Shared-story counts are live from our verified record — not editorial picks.
A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Source: maitlandmercury.com.au · ulladullatimes.com.au
Experts are calling for a radical shift in antibiotic procurement, moving toward a subscription-based 'Netflix model' to incentivize the development of new drugs against resistant superbugs. This approach aims to decouple pharmaceutical revenue from sales volume, ensuring a steady supply of critical treatments as antimicrobial resistance escalates globally.
Australian Government is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
